Novo Nordisk And China’s BGI Sign Collaboration Agreement
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk Agreement With China’s BGI combines Novo’s drug development experience with BGI’s next-generation sequencing capabilities and bioinformatics.